Tratar el tumor cerebral pediátrico

Luciano Di Croce

Centre for Genomic Regulation (CRG), Barcelona, Spain

Diffuse midline glioma is the most aggressive and deadly paediatric brain tumour. It is a very rare disease that affects between 300 and 400 children aged 6 to 12 in Europe each year. Its prognosis is dire, with less than two years of survival following diagnosis, due to the lack of effective treatments. Currently, the only therapy available is radiotherapy, which is applied to slow the growth of the tumour, although it is not curative.

This project aims to advance the development of a new therapy that could offer hope for these patients and their families. In previous work, the researchers leading the project have developed preclinical models that have allowed them to validate the tumour vulnerabilities identified in the laboratory. Using genetic tools and existing chemical compounds aimed at the main targets, they have been able to stop tumour growth in vivo.

Building on the promising results achieved in previous work, in the current project the team will continue to advance the identification and validation of these industrially valuable chemical compounds as a new treatment for this hitherto incurable disease.

Chemical inhibition of novel Diffuse Midline Glioma vulnerabilities

Stage 1